Income Statement Indivior Pharmaceuticals, Inc.

Stocks

INDV

US45579U1097

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 20:35:20 11/06/2026 BST			5-day change	1st Jan Change
38.50 ^USD	+1.09%		+2.67%	+7.16%

06-10	Indivior Pharmaceuticals Insider Sold Shares Worth $1,357,200, According to a Recent SEC Filing	MT
05-20	Indivior Pharmaceuticals Announces Findings From Real-World Evidence Studies on Monthly Injectable Buprenorphine	CI

dfcd00050047715cc1989ea88dd8d._Mxrz9wURpv-IVcnLmh-8lEpyzxzCj4MQu5l0Vuv5r8.tqcZ-ohnMN6vcRpAV1s_twJ5pX4ARl8hGNhdmALAlM7KuVmpqlwL3KRVAg

Published financial data: INDIVIOR PHARMACEUTICALS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	791M	901M	1.09B	1.19B	1.24B
Total Revenues	791M	901M	1.09B	1.19B	1.24B
Cost of Goods Sold, Total	127M	159M	186M	190M	198M
Gross Profit	664M	742M	907M	998M	1.04B
Selling General & Admin Expenses, Total	425M	461M	543M	606M	578M
R&D Expenses	52M	72M	106M	107M	80M
Other Operating Expenses	-	-3M	-2M	-5M	-4M
Other Operating Expenses, Total	477M	530M	647M	708M	654M
Operating Income	187M	212M	260M	290M	387M
Interest Expense, Total	-18M	-22M	-30M	-41M	-45M
Interest And Investment Income	1M	18M	43M	23M	22M
Net Interest Expenses	-17M	-4M	13M	-18M	-23M
Other Non Operating Income (Expenses)	3M	1M	-1M	-1M	-
EBT, Excl. Unusual Items	173M	209M	272M	271M	364M
Restructuring Charges	1M	-	-	-53M	-121M
Gain (Loss) On Sale Of Investments	-	-	-	-9M	-1M
Gain (Loss) On Sale Of Assets	20M	-	-	-	-
Asset Writedown	-	-	-	-	-
In Process R&D Expenses	-	-	-	-1M	-
Insurance Settlements	12M	5M	1M	-	-
Legal Settlements	-14M	-303M	-247M	-195M	-3M
Other Unusual Items	-2M	-6M	-25M	-	-
EBT, Incl. Unusual Items	190M	-95M	1M	13M	239M
Income Tax Expense	-15M	-42M	-1M	11M	29M
Earnings From Continuing Operations	205M	-53M	2M	2M	210M
Net Income to Company	205M	-53M	2M	2M	210M
Net Income - (IS)	205M	-53M	2M	2M	210M
Net Income to Common Incl Extra Items	205M	-53M	2M	2M	210M
Net Income to Common Excl. Extra Items	205M	-53M	2M	2M	210M
Per Share Items
Net EPS - Basic	1.41	-0.38	0.01	0.02	1.68
Basic EPS - Continuing Operations	1.41	-0.38	0.01	0.02	1.68
Basic Weighted Average Shares Outstanding	146M	139M	137M	132M	125M
Net EPS - Diluted	1.35	-0.38	0.01	0.02	1.64
Diluted EPS - Continuing Operations	1.35	-0.38	0.01	0.02	1.64
Diluted Weighted Average Shares Outstanding	154M	139M	142M	133M	128M
Normalized Basic EPS	0.74	0.94	1.24	1.28	1.82
Normalized Diluted EPS	0.7	0.94	1.2	1.27	1.78
Payout Ratio	-	-	-	-	-
American Depositary Receipts Ratio (ADR)	1	1	1	1	1
Supplemental Items
EBITDA	199M	223M	269M	316M	397M
EBITA	193M	217M	262M	290M	387M
EBIT	187M	212M	260M	290M	387M
EBITDAR	-	-	-	328M	409M
Effective Tax Rate - (Ratio)	-7.89	44.21	-100	84.62	12.13
Current Domestic Taxes	-	-	-	-6M	76M
Current Foreign Taxes	-	-	-	11M	-1M
Total Current Taxes	3M	64M	55M	5M	75M
Deferred Domestic Taxes	-	-	-	25M	28M
Deferred Foreign Taxes	-	-	-	-19M	-74M
Total Deferred Taxes	-18M	-106M	-56M	6M	-46M
Normalized Net Income	108M	131M	170M	169M	228M
Interest Capitalized	-	-	-	3M	5M
Interest on Long-Term Debt	2M	2M	3M	35M	47M
Non-Cash Pension Expense	-	-	-	-	-
Supplemental Operating Expense Items
Advertising Expense	-	-	-	68M	124M
Selling and Marketing Expenses	-	-	-	68M	124M
Research And Development Expense From Footnotes	52M	72M	106M	108M	97M
Net Rental Expense, Total	-	-	-	12M	12M
Imputed Operating Lease Interest Expense	-	-	-	12.84M	13.22M
Imputed Operating Lease Depreciation	-	-	-	-839K	-1.22M
Stock-Based Comp., SG&A Exp. (Total)	-	-	-	-	26M
Stock-Based Comp., Other (Total)	11M	16M	22M	24M	-
Total Stock-Based Compensation	11M	16M	22M	24M	26M

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	1.1B	774M	316M	319M	195M
Short Term Investments	-	109M	84M	1M	-
Trading Asset Securities, Total	-	10M	10M	-	-
Total Cash And Short Term Investments	1.1B	893M	410M	320M	195M
Accounts Receivable, Total	202M	220M	254M	254M	253M
Other Receivables	13M	5M	-	34M	2M
Total Receivables	215M	225M	254M	288M	255M
Inventory	95M	114M	142M	178M	153M
Prepaid Expenses	18M	14M	23M	53M	34M
Other Current Assets, Total	14M	13M	434M	-	15M
Total Current Assets	1.44B	1.26B	1.26B	839M	652M
Gross Property Plant And Equipment	169M	162M	198M	229M	277M
Accumulated Depreciation	-74M	-77M	-81M	-90M	-107M
Net Property Plant And Equipment	95M	85M	117M	139M	170M
Long-term Investments	-	98M	41M	27M	28M
Goodwill	-	-	5M	-	-
Other Intangibles, Total	82M	70M	232M	6M	2M
Deferred Tax Assets Long-Term	105M	219M	268M	280M	323M
Other Long-Term Assets, Total	106M	38M	28M	28M	26M
Total Assets	1.83B	1.77B	1.95B	1.32B	1.2B
Liabilities
Accounts Payable, Total	137M	36M	39M	62M	48M
Accrued Expenses, Total	147M	581M	704M	732M	784M
Current Portion of Long-Term Debt	3M	3M	3M	18M	29M
Current Portion of Leases	8M	8M	9M	10M	10M
Current Income Taxes Payable	7M	9M	18M	7M	2M
Other Current Liabilities	502M	382M	532M	110M	41M
Total Current Liabilities	804M	1.02B	1.3B	939M	914M
Long-Term Debt	239M	237M	236M	315M	290M
Long-Term Leases	36M	29M	34M	32M	22M
Pension & Other Post Retirement Benefits	3M	-	-	-	-
Other Non Current Liabilities	547M	433M	379M	381M	73M
Total Liabilities	1.63B	1.72B	1.95B	1.67B	1.3B
Common Stock, Total	70M	68M	68M	62M	62M
Additional Paid In Capital	7M	8M	11M	90M	112M
Retained Earnings	1.44B	1.3B	1.24B	-454M	-243M
Comprehensive Income and Other	-1.31B	-1.33B	-1.32B	-46M	-29M
Total Common Equity	203M	51M	0	-348M	-98M
Total Equity	203M	51M	0	-348M	-98M
Total Liabilities And Equity	1.83B	1.77B	1.95B	1.32B	1.2B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	140M	136M	136M	125M	125M
ECS Total Common Shares Outstanding	140M	136M	137M	125M	125M
Book Value / Share	1.44	0.37	0	-2.78	-0.78
Tangible Book Value	121M	-19M	-237M	-354M	-100M
Tangible Book Value Per Share	0.86	-0.14	-1.74	-2.83	-0.8
Total Debt	286M	277M	282M	375M	351M
Net Debt	-816M	-616M	-128M	55M	156M
Debt Equivalent Oper. Leases	-	-	-	96M	96M
Account Code - Inventory Valuation	5	5	5	5	5
Inventories - Raw Materials, Total	34M	27M	38M	33M	-
Inventories - Work In Process, Total	28M	42M	34M	51M	-
Inventories - Finished Goods, Total	33M	45M	70M	94M	-
Land - (BS)	55M	51M	69M	76M	111M
Machinery, Total	77M	80M	96M	76M	76M
Full Time Employees	885	928	1.16K	1.03K	827
Part Time Employees	-	-	-	21	11
Accumulated Allowance for Doubtful Accounts (Supple)	3M	2M	2M	3M	4M

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	205M	-53M	2M	2M	210M
Depreciation & Amortization - CF	13M	14M	16M	26M	20M
Amortization of Goodwill and Intangible Assets - (CF)	6M	5M	2M	-	-
Depreciation & Amortization, Total	19M	19M	18M	26M	20M
Amortization of Deferred Charges, Total - (CF)	3M	2M	10M	3M	-
(Gain) Loss From Sale Of Asset	-20M	-1M	-	-	-
(Gain) Loss on Sale of Investments - (CF)	-	-	-	9M	-
Asset Writedown & Restructuring Costs	-	-	-	8M	19M
Stock-Based Compensation (CF)	11M	16M	22M	24M	26M
Other Operating Activities, Total	-38M	-112M	-62M	5M	-45M
Change In Accounts Receivable	-25M	-21M	-33M	-1M	3M
Change In Inventories	-3M	-25M	-21M	-45M	18M
Change In Accounts Payable	201M	-98M	115M	-	-
Change in Other Net Operating Assets	0	269M	-366M	5M	-278M
Cash from Operations	353M	-4M	-315M	36M	-27M
Capital Expenditure	-4M	-5M	-8M	-29M	-66M
Cash Acquisitions	-	-	-129M	-	-
Sale (Purchase) of Intangible assets	-10M	0	-45M	-2M	-1M
Investment in Marketable and Equity Securities, Total	-	-218M	84M	100M	0
Other Investing Activities, Total	-	-	-	-	1M
Cash from Investing	-14M	-223M	-98M	69M	-66M
Long-Term Debt Issued, Total	250M	-	-	332M	-
Total Debt Issued	250M	-	-	332M	-
Long-Term Debt Repaid, Total	-244M	-12M	-20M	-240M	-17M
Total Debt Repaid	-244M	-12M	-20M	-240M	-17M
Issuance of Common Stock	1M	2M	4M	3M	2M
Repurchase of Common Stock	-101M	-90M	-33M	-195M	-16M
Common Dividends Paid	-	-	-	-	-
Common & Preferred Stock Dividends Paid	-	-	-	-	-
Other Financing Activities, Total	-	-	3M	-2M	1M
Cash from Financing	-94M	-100M	-46M	-102M	-30M
Foreign Exchange Rate Adjustments	-1M	-1M	1M	-	-1M
Net Change in Cash	244M	-328M	-458M	3M	-124M
Supplemental Items
Cash Interest Paid	18M	24M	32M	-	-
Cash Income Tax Paid (Refund)	17M	57M	33M	-	38M
Levered Free Cash Flow	318M	342M	-61.25M	148M	222M
Unlevered Free Cash Flow	329M	356M	-42.5M	173M	250M
Change In Net Working Capital	-193M	-191M	202M	30M	-29M
Net Debt Issued / Repaid	6M	-12M	-20M	92M	-17M

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	6.95	7.36	8.73	11.77	19.22
Return on Total Capital	27.31	32.44	53.28	304.62	166.24
Return On Equity %	143.86	-41.73	7.84	-0.74	-96.55
Return on Common Equity	143.86	-41.73	7.84	-0.74	-96.55
Margin Analysis
Gross Profit Margin %	83.94	82.35	82.98	84.01	84.02
SG&A Margin	53.73	51.17	49.68	51.01	46.65
EBITDA Margin %	25.16	24.75	24.61	26.6	32.04
EBITA Margin %	24.4	24.08	23.97	24.41	31.23
EBIT Margin %	23.64	23.53	23.79	24.41	31.23
Income From Continuing Operations Margin %	25.92	-5.88	0.18	0.17	16.95
Net Income Margin %	25.92	-5.88	0.18	0.17	16.95
Net Avail. For Common Margin %	25.92	-5.88	0.18	0.17	16.95
Normalized Net Income Margin	13.67	14.5	15.55	14.26	18.36
Levered Free Cash Flow Margin	40.15	37.93	-5.6	12.43	17.9
Unlevered Free Cash Flow Margin	41.58	39.46	-3.89	14.58	20.17
Asset Turnover
Asset Turnover	0.47	0.5	0.59	0.77	0.98
Fixed Assets Turnover	7.99	10.01	10.82	9.03	8.02
Receivables Turnover (Average Receivables)	4.15	4.27	4.61	4.68	4.89
Inventory Turnover (Average Inventory)	1.35	1.52	1.45	1.21	1.24
Short Term Liquidity
Current Ratio	1.8	1.24	0.97	0.89	0.71
Quick Ratio	1.64	1.1	0.51	0.65	0.49
Operating Cash Flow to Current Liabilities	0.44	-0	-0.24	0.04	-0.03
Days Sales Outstanding (Average Receivables)	87.9	85.48	79.14	78.25	74.68
Days Outstanding Inventory (Average Inventory)	270.16	239.89	251.18	301.47	294.95
Average Days Payable Outstanding	222.11	177.37	61.4	79.33	110.09
Cash Conversion Cycle (Average Days)	135.95	147.99	268.93	300.39	259.53
Long Term Solvency
Total Debt/Equity	140.89	543.14	-	-107.76	-358.16
Total Debt / Total Capital	58.49	84.45	100	1.39K	138.74
LT Debt/Equity	135.47	521.57	-	-99.71	-318.37
Long-Term Debt / Total Capital	56.24	81.1	95.74	1.29K	123.32
Total Liabilities / Total Assets	88.92	97.12	100	126.38	108.16
EBIT / Interest Expense	10.39	9.64	8.67	7.07	8.6
EBITDA / Interest Expense	11.44	10.5	9.27	8	9.09
(EBITDA - Capex) / Interest Expense	11.22	10.27	9	7.29	7.62
Total Debt / EBITDA	1.39	1.2	1.01	1.14	0.86
Net Debt / EBITDA	-3.96	-2.67	-0.46	0.17	0.38
Total Debt / (EBITDA - Capex)	1.42	1.23	1.04	1.25	1.02
Net Debt / (EBITDA - Capex)	-4.04	-2.73	-0.47	0.18	0.45
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	22.26	13.91	21.31	8.69	4.29
Gross Profit, 1 Yr. Growth %	19.64	11.75	22.24	8.6	4.31
EBITDA, 1 Yr. Growth %	97.03	12.06	21.17	23.92	28.48
EBITA, 1 Yr. Growth %	105.32	12.44	21.3	19.34	30.74
EBIT, 1 Yr. Growth %	112.5	13.37	23.22	19.34	30.74
Earnings From Cont. Operations, 1 Yr. Growth %	-238.51	-125.85	-103.77	-101.55	2.9K
Net Income, 1 Yr. Growth %	-238.51	-125.85	-103.77	-101.55	2.9K
Normalized Net Income, 1 Yr. Growth %	121.79	21.51	30.77	7.54	30.94
Diluted EPS Before Extra, 1 Yr. Growth %	-233.7	-128.24	-102.62	-101.61	3.18K
Accounts Receivable, 1 Yr. Growth %	12.85	8.91	15.45	0	-0.39
Inventory, 1 Yr. Growth %	2.15	20	24.56	31.85	-8.38
Net Property, Plant and Equip., 1 Yr. Growth %	-7.77	-10.53	37.65	12.1	22.3
Total Assets, 1 Yr. Growth %	19.66	-3.44	10.46	-25.06	-8.74
Tangible Book Value, 1 Yr. Growth %	505	-115.7	1.15K	73.53	-70.85
Common Equity, 1 Yr. Growth %	147.56	-74.88	-100	82.2	-70.92
Cash From Operations, 1 Yr. Growth %	-282.9	-101.13	7.78K	-112	-175
Capital Expenditures, 1 Yr. Growth %	0	25	60	262.5	127.59
Levered Free Cash Flow, 1 Yr. Growth %	-415.65	7.6	-117.96	-237.97	50.47
Unlevered Free Cash Flow, 1 Yr. Growth %	-465.42	8.1	-111.98	-303.52	44.44
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	0.38	18.01	17.55	14.83	6.47
Gross Profit, 2 Yr. CAGR %	1.46	15.63	16.87	15.35	6.43
EBITDA, 2 Yr. CAGR %	-3.57	48.59	16.27	17.73	23.81
EBITA, 2 Yr. CAGR %	-3.44	51.94	16.51	16.14	25.17
EBIT, 2 Yr. CAGR %	-3.78	55.21	17.91	16.14	25.17
Earnings From Cont. Operations, 2 Yr. CAGR %	23.69	-40.16	-90.12	-78.68	29.1
Net Income, 2 Yr. CAGR %	23.69	-40.16	-90.12	-78.68	29.1
Normalized Net Income, 2 Yr. CAGR %	-8.36	63.69	25.39	14.14	19.24
Diluted EPS Before Extra, 2 Yr. CAGR %	22.47	-38.55	-91.39	-78.24	33.51
Accounts Receivable, 2 Yr. CAGR %	2.57	10.86	12.14	7.45	-0.2
Inventory, 2 Yr. CAGR %	14.08	10.72	22.26	24.96	6.46
Net Property, Plant and Equip., 2 Yr. CAGR %	-5.77	-9.16	10.98	27.88	17.09
Total Assets, 2 Yr. CAGR %	5.31	7.49	3.28	-13.65	-17.39
Tangible Book Value, 2 Yr. CAGR %	-6.02	-2.53	39.95	331.64	-29.99
Common Equity, 2 Yr. CAGR %	-1.45	-21.14	-	161.22	-28.37
Cash From Operations, 2 Yr. CAGR %	52.9	-85.6	-5.54	200	-70
Capital Expenditures, 2 Yr. CAGR %	-24.41	11.8	41.42	140.83	187.23
Levered Free Cash Flow, 2 Yr. CAGR %	38.43	84.29	-56.09	-33.67	45.67
Unlevered Free Cash Flow, 2 Yr. CAGR %	35.83	98.75	-64.05	-29.88	73.9
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-7.67	4.7	19.1	14.52	11.2
Gross Profit, 3 Yr. CAGR %	-8.86	4.78	17.79	14.55	11.55
EBITDA, 3 Yr. CAGR %	-16.43	1.38	38.62	16.67	20.31
EBITA, 3 Yr. CAGR %	-16.79	1.58	40.73	14.54	21.64
EBIT, 3 Yr. CAGR %	-17.42	1.62	43.49	15.75	21.64
Earnings From Cont. Operations, 3 Yr. CAGR %	-9.33	-26.6	-76.18	-78.63	68.37
Net Income, 3 Yr. CAGR %	-9.33	-26.6	-76.18	-78.63	68.37
Normalized Net Income, 3 Yr. CAGR %	-18.37	0.48	51.64	16.14	20.51
Diluted EPS Before Extra, 3 Yr. CAGR %	-9.97	-24.9	-78.53	-77.61	72.41
Accounts Receivable, 3 Yr. CAGR %	-9.11	4.64	12.37	7.93	4.77
Inventory, 3 Yr. CAGR %	6.79	16.02	15.15	23.28	10.31
Net Property, Plant and Equip., 3 Yr. CAGR %	18.56	-7.39	4.34	13.53	25.99
Total Assets, 3 Yr. CAGR %	5.8	2.31	8.47	-10.37	-12.11
Tangible Book Value, 3 Yr. CAGR %	88.73	-48.24	127.98	43.02	73.95
Common Equity, 3 Yr. CAGR %	45.43	-37.51	-	19.68	24.32
Cash From Operations, 3 Yr. CAGR %	5.22	-70.19	17.74	-53.28	88.99
Capital Expenditures, 3 Yr. CAGR %	-28.62	-10.61	25.99	93.54	136.33
Levered Free Cash Flow, 3 Yr. CAGR %	25.39	27.28	-15.25	-22.54	-12.89
Unlevered Free Cash Flow, 3 Yr. CAGR %	22.14	25.87	-22.13	-19.24	-10.83
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-5.65	-3.79	1.69	8.64	13.88
Gross Profit, 5 Yr. CAGR %	-7.15	-5.58	0.68	9.12	13.4
EBITDA, 5 Yr. CAGR %	-12.99	2.3	-4.63	8.11	31.49
EBITA, 5 Yr. CAGR %	-13.43	2.37	-4.8	6.98	32.71
EBIT, 5 Yr. CAGR %	-13.54	1.9	-4.77	7.5	34.48
Earnings From Cont. Operations, 5 Yr. CAGR %	42.41	-1.79	-62.65	-56.87	7.25
Net Income, 5 Yr. CAGR %	42.41	-1.79	-62.65	-56.87	7.25
Normalized Net Income, 5 Yr. CAGR %	-12.43	6.72	-3.08	5.64	36.08
Diluted EPS Before Extra, 5 Yr. CAGR %	40.9	-0.96	-64.8	-55.82	10.19
Accounts Receivable, 5 Yr. CAGR %	-0.29	-3.06	-1.14	5.76	7.17
Inventory, 5 Yr. CAGR %	18.3	17	12.73	19.51	10.47
Net Property, Plant and Equip., 5 Yr. CAGR %	28.61	9.5	15.47	5.37	10.54
Total Assets, 5 Yr. CAGR %	8.67	4.14	4.78	-4.4	-4.74
Tangible Book Value, 5 Yr. CAGR %	-20.37	-42.22	67.45	20.91	37.97
Common Equity, 5 Yr. CAGR %	-7.2	-24.14	-	10.74	3.63
Cash From Operations, 5 Yr. CAGR %	-2.81	-57.69	0.78	-24.93	-32.52
Capital Expenditures, 5 Yr. CAGR %	-27.52	-30.12	-6.17	32.88	75.18
Levered Free Cash Flow, 5 Yr. CAGR %	-9.13	38.11	-17.59	-2.29	17.12
Unlevered Free Cash Flow, 5 Yr. CAGR %	-9.67	56.91	-25.12	-0.57	22.66